טוען...

Synergistic effects of the immune checkpoint inhibitor CTLA-4 combined with the growth inhibitor lycorine in a mouse model of renal cell carcinoma

Renal cell carcinoma (RCC) management has undergone a major transformation over the past decade; immune checkpoint inhibitors are currently undergoing clinical trials and show promising results. However, the effectiveness of immune checkpoint inhibitors in patients with metastatic RCC (mRCC) is stil...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncotarget
Main Authors: Li, Xiezhao, Xu, Peng, Wang, Chongshan, Xu, Naijin, Xu, Abai, Xu, Yawen, Sadahira, Takuya, Araki, Motoo, Wada, Koichiro, Matsuura, Eiji, Watanabe, Masami, Zheng, Junxia, Sun, Pinghua, Huang, Peng, Nasu, Yasutomo, Liu, Chunxiao
פורמט: Artigo
שפה:Inglês
יצא לאור: Impact Journals LLC 2017
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400575/
https://ncbi.nlm.nih.gov/pubmed/28416753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15505
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!